Wyeth Launch Of Effexor Follow-On May Await Low-Dose Data

Wyeth may postpone launch of its investigational antidepressant DVS-233 (desvenlafaxine extended release) while it collects data on a lower dose of the Effexor follow-on, pending the resolution of manufacturing issues